摘要
目的:探讨替雷利珠单抗联合PC方案(培美曲塞+顺铂)治疗晚期肺癌患者的效果。方法:选取2021年2月至2022年2月该院收治的晚期肺癌患者82例,采用计算机随机数字生成法分为观察组(n=41)、对照组(n=41)。对照组患者采用PC方案治疗,观察组患者在对照组的基础上联合应用替雷利珠单抗。比较两组患者的疾病缓解率及不良反应发生情况;比较两组患者治疗前、治疗2个周期和4个周期后血清癌胚抗原(CEA)、糖类抗原125(CA125)和细胞角蛋白19片段(CYFRA21-1)水平,T淋巴细胞水平,血清磷脂酰肌醇3激酶(PI3K)、蛋白激酶B(Akt)水平。结果:观察组患者的疾病缓解率为56.10%(23/41),高于对照组的34.15%(14/41),差异有统计学意义(P<0.05)。治疗2个周期、4个周期后,两组患者血清CEA、CA125、CYFRA21-1、PI3K和Akt水平低于治疗前,且治疗4个周期后两组患者上述指标水平低于治疗2个周期后,观察组患者上述指标水平低于对照组,差异均有统计学意义(P<0.05)。治疗2个周期、4个周期后,观察组患者CD3+、CD4+和CD4+/CD8+水平高于治疗前,且高于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:替雷利珠单抗联合PC方案治疗晚期肺癌的疗效确切,可降低肿瘤标志物水平,抑制PI3K/Akt信号通路,增强免疫功能,安全可靠。
OBJECTIVE:To probe into the effects of tislelizumab combined with PC regimen(pemetrexed+cisplatin)in the treatment of advanced lung cancer.METHODS:Totally 82 patients with advanced lung cancer in the hospital from Feb.2021 to Feb.2022 were extracted to be divided into the observation group(n=41)and the control group(n=41)via the random number table method.The control group was treated with PC regimen,while the observation group received tislelizumab on the basis of the control group.The disease remission rate and adverse reactions were compared between two groups.Before treatment,after 2 cycles of treatment and after 4 cycles of treatment,the levels of serum carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)and cytokeratin 19 fragment(CYFRA21-1),T lymphocytes,serum phosphatidylinositol-3 kinase(PI3K)and protein kinase B(Akt)were compared between two groups.RESULTS:The disease remission rate of 56.10%(23/41)in the observation group was higher than that of 34.15%(14/41)in the control group,with statistically significant difference(P<0.05).After 2 cycles of treatment and after 4 cycles of treatment,the serum levels of CEA,CA125,CYFRA21-1,PI3K and Akt in two groups were lower than those before treatment,and after 4 cycles of treatment were lower than after 2 cycles of treatment,and the observation group were lower than the control group,with statistically significant differences(P<0.05).After 2 cycles of treatment and after 4 cycles of treatment,the levels of CD3+,CD4+,CD4+/CD8+in the observation group were higher than those before treatment and higher than those in the control group,with statistically significant differences(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).CONCLUSIONS:The efficacy of tislelizumab combined with PC regimen in the treatment of advanced lung cancer is significant,which can reduce the level of tumor markers,inhibit the PI3K/Akt signaling pathway and enhance immune function with higher safety.
作者
王渊
谭盼
张靖
WANG Yuan;TAN Pan;ZHANG Jing(Dept.of Cardiothoracic Surgery,Qianjiang Hospital Affiliated to Chongqing University,Chongqing409000,China)
出处
《中国医院用药评价与分析》
2023年第3期268-271,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
重庆市卫生计生委医学科研计划面上项目(No.2020MSXM030151)。
